SV2A
Basic information
Region (hg38): 1:149903318-149917844
Links
Phenotypes
GenCC
Source:
- epilepsy (Limited), mode of inheritance: AD
- developmental and epileptic encephalopathy 113 (Limited), mode of inheritance: AR
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Developmental and epileptic encephalopathy 113 | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Craniofacial; Musculoskeletal; Neurologic | 26002053; 37985816 |
ClinVar
This is a list of variants' phenotypes submitted to
- not_specified (71 variants)
- not_provided (18 variants)
- Developmental_and_epileptic_encephalopathy_113 (3 variants)
- Inborn_genetic_diseases (1 variants)
- See_cases (1 variants)
- SV2A-related_disorder (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SV2A gene is commonly pathogenic or not. These statistics are base on transcript: NM_000014849.5. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 13 | 19 | ||||
| missense | 68 | 70 | ||||
| nonsense | 2 | |||||
| start loss | 0 | |||||
| frameshift | 0 | |||||
| splice donor/acceptor (+/-2bp) | 0 | |||||
| Total | 1 | 1 | 69 | 15 | 5 |
Highest pathogenic variant AF is 0.0000020522025
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| SV2A | protein_coding | protein_coding | ENST00000369146 | 12 | 14565 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 0.228 | 0.772 | 125733 | 0 | 15 | 125748 | 0.0000596 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 2.12 | 328 | 455 | 0.721 | 0.0000285 | 4853 |
| Missense in Polyphen | 84 | 198.11 | 0.42401 | 2202 | ||
| Synonymous | 0.200 | 185 | 189 | 0.981 | 0.0000123 | 1501 |
| Loss of Function | 4.36 | 9 | 38.0 | 0.237 | 0.00000246 | 366 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.000123 | 0.000123 |
| Ashkenazi Jewish | 0.0000992 | 0.0000992 |
| East Asian | 0.000109 | 0.0000544 |
| Finnish | 0.00 | 0.00 |
| European (Non-Finnish) | 0.0000704 | 0.0000703 |
| Middle Eastern | 0.000109 | 0.0000544 |
| South Asian | 0.0000654 | 0.0000653 |
| Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission. Positively regulates vesicle fusion by maintaining the readily releasable pool of secretory vesicles (By similarity). {ECO:0000250}.;
- Pathway
- ECM-receptor interaction - Homo sapiens (human);Disease;Toxicity of botulinum toxin type A (BoNT/A);Toxicity of botulinum toxin type D (BoNT/D);Toxicity of botulinum toxin type F (BoNT/F);Uptake and actions of bacterial toxins;Neurotoxicity of clostridium toxins;Infectious disease;Toxicity of botulinum toxin type E (BoNT/E)
(Consensus)
Recessive Scores
- pRec
- 0.345
Intolerance Scores
- loftool
- 0.393
- rvis_EVS
- -1.24
- rvis_percentile_EVS
- 5.41
Haploinsufficiency Scores
- pHI
- 0.903
- hipred
- Y
- hipred_score
- 0.639
- ghis
- 0.571
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.126
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Sv2a
- Phenotype
- behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); growth/size/body region phenotype; cellular phenotype;
Gene ontology
- Biological process
- cellular calcium ion homeostasis;regulation of gamma-aminobutyric acid secretion;synaptic vesicle priming;transmembrane transport
- Cellular component
- endoplasmic reticulum;plasma membrane;cell-cell junction;synaptic vesicle;integral component of membrane;integral component of synaptic vesicle membrane;dendrite;synaptic vesicle membrane;neuromuscular junction;neuron projection;neuronal cell body;presynaptic active zone;glutamatergic synapse;GABA-ergic synapse
- Molecular function
- protein kinase binding;transmembrane transporter activity